Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine and inflammatory response in coronary artery disease
2020-000656-35Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of colchicine in coronary arteriosclerosis and atherosclerosis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in inflammatory cytokine release after colchicine vs no colchicine. Started May 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on 2020-000656-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000656-35.